FAQ: Oragenics Inc.'s Participation in BIO 2025 and Neurotrauma Symposium

What is Oragenics Inc. presenting at the BIO 2025 and Neurotrauma Symposium?

Oragenics Inc. is presenting ONP-002, its intranasal neurosteroid candidate for concussion treatment, at both the 2025 BIO International Convention and the 42nd Annual National Neurotrauma Society Symposium.

Why is Oragenics Inc.’s participation in these events significant?

These events provide Oragenics Inc. with critical platforms to showcase ONP-002 to global leaders in neuroscience and pharmaceutical sectors, potentially advancing its development and application in treating concussions.

Who from Oragenics Inc. will be presenting at the BIO 2025?

Greg Gironda, Head of Business Development at Oragenics Inc., will be presenting at the 2025 BIO International Convention.

When and where are the BIO 2025 and Neurotrauma Symposium taking place?

The 2025 BIO International Convention is scheduled from June 16–19 in Boston, while the 42nd Annual National Neurotrauma Society Symposium will take place from June 15–18 in Philadelphia.

What is ONP-002?

ONP-002 is Oragenics Inc.’s intranasal neurosteroid candidate designed for the treatment of concussions, representing a novel approach in neurology and pharmaceutical treatments.

Where can I find more information about Oragenics Inc.?

More information about Oragenics Inc. can be found on their website at www.Oragenics.com or in their newsroom at https://ibn.fm/OGEN.

What other areas is Oragenics Inc. focused on besides concussion treatment?

Besides concussion treatment, Oragenics Inc. is also focused on fighting infectious diseases, treating Niemann Pick Disease Type C (NPC), and developing proprietary powder formulations and an intranasal delivery device.

How can I stay updated on Oragenics Inc.’s latest news?

The latest news and updates relating to Oragenics Inc. (OGEN) are available in the company’s newsroom at https://ibn.fm/OGEN.